Previous close | 1.4300 |
Open | 1.4000 |
Bid | 1.3500 x 100 |
Ask | 1.4400 x 100 |
Day's range | 1.3500 - 1.4201 |
52-week range | 1.2100 - 7.9700 |
Volume | |
Avg. volume | 155,062 |
Market cap | 48.501M |
Beta (5Y monthly) | 1.12 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
CLEARWATER, Fla., April 25, 2024--Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2024 will be released before the market opens on Thursday, May 9th.
CLEARWATER, Fla., April 11, 2024--Apyx® Medical Corporation (NASDAQ:APYX) (the "Apyx Medical"; "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce the Renuvion Users’ Summit is taking place in Las Vegas from April 12-13, 2024.
CLEARWATER, Fla., March 21, 2024--Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its fourth quarter and full year ended December 31, 2023, and introduced financial expectations for the full year ending December 31, 2024.